Inhibiting macrophage MerTK signaling creates an innate immune response against cancer

July 8, 2013

The tyrosine kinase MerTK plays a prominent role in the body's immune response. MerTK signaling helps "calm" the body's first line of immunity, the macrophage, while it performs the routine duties - clearing cells that die and healing damaged tissue.

New evidence by a University of North Carolina-led team published online on July 8 by the Journal of Clinical Investigation shows that MerTK macrophage action in the microenvironment that surrounds cancer cells blunts the immune response, allowing the tumor cell to grow and metastasize. The study, led by senior author Shelley Earp, MD, director of the UNC Lineberger Comprehensive Cancer Center, used mouse models bred without the gene for MerTK. Their work determined that MerTK absence increased the anti-tumor response and slowed the growth and spread of model breast, colon and skin cancers.

Several new drugs have recently been approved that effectively stimulate anti-tumor immunity. The evidence from the UNC researchers indicates that inhibiting MerTK in combination with these existing therapies may offer another avenue by which to activate the immune system in the fight against cancer.

Under normal circumstances, macrophages rid the body of normal debris while MerTK signaling evokes a wound healing, tissue repair response. With infection, the innate immune system, led by the macrophage, helps create an "angry" response aimed at eliminating foreign material.

UNC researchers theorized that, in the case of cancer cells derived from the cells of the body, MerTK action in the microenvironment surrounding the tumor cells might suppress the anti-tumor response and keep the immune system's T lymphovcytes from becoming active and killing tumor cells.

"In the first years of everyone's life, the immune system is 'educated' to tell the difference between 'self' and a foreign invader. Since tumor cells are part of our selves the immune system, unfortunately, becomes tolerant and fails to reject the tumor," said Dr. Earp.

Using model tumors, the research team examined the response of breast, skin and colon cancers growing in a mouse that lacked MerTK. They discovered that the tumors showed slower growth and a lower propensity to metastasize to other parts of the body. In the normal mouse, the MerTK macrophage signals were those of the wound healing type; whereas in the absence of MerTK, the entire immune system was activated, promoting inflammation.

"Our work strongly indicates that if you could inhibit MerTK signaling in the tumor bed, you could trigger a more active immune system leading to a stronger T-cell killing response against the tumor," said Dr. Earp.

While utilizing the immune system in the fight against cancer has been a goal of researchers for decades, the last four years have seen the development and approval of several drugs – including the monoclonal antibodies Ipilimumab and Tremelimumab – that prolong the anti-tumor T-cell response, resulting in clinical benefit particularly in melanoma. In some patients, these therapies have shown the ability not only to destroy cancer cells, but also to prevent the relapses that plague chemotherapy and even newer targeted agents.

The UNC Lineberger team is collaborating with the UNC Chemical Biology and Drug Discovery Center to discover, develop and test oral drugs that inhibit MerTK activity: compounds are currently being tested in animal models.

"We hope to create a new, more MerTK selective tool with which to stimulate the initial tumor response and combine this strategy with the existing drugs that extend the immune response. If we can initiate a stronger response and sustain that activity we may be more effective in treating metastatic cancer," said Dr Earp. "Tumor cells can move throughout the body thwarting some of our best therapeutic interventions. The immune system is mobile and may be able to help eliminate tumor cells even at distant sites."

Explore further: Ovarian cancer cells hijack surrounding tissues to enhance tumor growth

More information: MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis, J Clin Invest. doi:10.1172/JCI67655

Related Stories

Ovarian cancer cells hijack surrounding tissues to enhance tumor growth

September 4, 2012
Tumor growth is dependent on interactions between cancer cells and adjacent normal tissue, or stroma. Stromal cells can stimulate the growth of tumor cells; however it is unclear if tumor cells can influence the stroma.

Endotrophin links obesity to breast cancer progression

October 8, 2012
Fat cells (adipocytes) surround breast tumors and contribute to tumor growth by expressing factors that aid oncogenesis. Col6 is a protein that is highly expressed in adipocytes and its expression is further increased in ...

New screening approach identifies small proteins unique to melanoma cells, researcher says

June 25, 2013
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein ...

New signaling pathway linked to breast cancer metastasis

April 2, 2012
Lymph nodes help to fight off infections by producing immune cells and filtering foreign materials from the body, such as bacteria or cancer cells. Thus, one of the first places that cancer cells are found when they leave ...

Targeted stimulation of immune pathway may help body fight back against liver cancer

June 5, 2013
Though it originates from the body's own cells, a tumor is as much of a hostile invader as any virus or bacterium. If the immune system is sufficiently sensitized, it can mount a counterattack just as it might fight an infection. ...

Your immune system: On surveillance in the war against cancer

May 9, 2013
Predicting outcomes for cancer patients based on tumor-immune system interactions is an emerging clinical approach, and new research from Wake Forest Baptist Medical Center is advancing the field when it comes to the most ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.